SmartDyeLivery receives phase I clinical trial approval
The Federal Institute for Drugs and Medical Devices (BfArM) has approved SmartDyeLivery GmbH’s entry into the clinical phase after reviewing the content of the application. Thus, for the first time, nanotransporters that are being developed for a specific therapy of septic liver failure can be tested on healthy subjects in a clinical setting.
